The present invention relates to diversely acetylated decasaccharides of formula (I) representative of two repeating units of Shigella flexneri serotype 2a O-antigen, conjugates and method of preparation thereof. These compounds exhibit antigenic properties and are particularly useful for the diagnosis of Shigella infection.
wherein R1 and R2 are as defined in claim 1.
GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X
申请人:Mulard Laurence
公开号:US20100239584A1
公开(公告)日:2010-09-23
The present invention relates to compounds derived from sugars which reproduce the epitopes of
Shigella flexneri
serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a
Shigella flexneri
infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
[EN] GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI<br/>[FR] GLYCOCONJUGUÉS ET LEUR UTILISATION EN TANT QUE VACCINS POTENTIELS CONTRE UNE INFECTION PAR SHIGELLA FLEXNERI
申请人:PASTEUR INSTITUT
公开号:WO2014067970A1
公开(公告)日:2014-05-08
The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)x-BCDA}n-(Y)y (X)x-CDAB}n-(Y)y (X)x-DABC}n-(Y)y (X)x-ABCD}n-(Y)y wherein A, B, C, D, X and Y, x, y and n are as defined in claim 1, said oligo- or polysaccharide being bound to a carrier.
Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
申请人:INSTITUT PASTEUR
公开号:EP2724730A1
公开(公告)日:2014-04-30
The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of:
(X)x-BCDA}n-(Y)y
(X)x-CDAB}n-(Y)y
(X)x-DABC}n-(Y)y
(X)x-ABCD}n-(Y)y
Wherein A, B, C, D, X and Y, x, y and n are as defined in claim 1,
said oligo- or polysaccharide being covalently bound to a carrier.
Structural Studies of the<i>O</i>-Acetyl-Containing O-Antigen from a<i>Shigella flexneri</i>Serotype 6 Strain and Synthesis of Oligosaccharide Fragments Thereof
作者:Pierre Chassagne、Carolina Fontana、Catherine Guerreiro、Charles Gauthier、Armelle Phalipon、Göran Widmalm、Laurence A. Mulard
DOI:10.1002/ejoc.201300180
日期:2013.7
spectroscopy of the delipidated lipopolysaccharide of Shigella flexneri serotype 6strain MDC 2924-71 confirmed the most recently reported structure of the O-antigen repeating unit as →4)-β-D-GalpA-(1→3)-β-D-GalpNAc-(1→2)-α-L-Rhap3Ac/4Ac-(1→2)-α-L-Rhap-(1→}, and revealed the non-stoichiometric acetylation at O-3C/4C. Input from the CASPER program helped to ascertain the fine distribution of the three possible
3C-O-乙酰化和非O-乙酰化目标是从常见的受保护中间体合成的。鼠李糖基化是通过使用亚胺酸酯供体最有效地实现的,包括在半乳糖醛酸苄酯受体的 O-4。相比之下,噻吩 2-脱氧-2-三氯乙酰胺-D-吡喃半乳糖苷前体优选用于涉及残基 B 的链延长。最终 Pd/C 介导的脱保护确保了 O-乙酰基稳定性。所有目标分子都代表了福氏链球菌 6 的 O 抗原的一部分,这是一种流行的血清型。非 O-乙酰化寡糖也是大肠杆菌 O147 O-抗原的片段。噻吩基 2-脱氧-2-三氯乙酰胺-D-吡喃半乳糖苷前体优选用于涉及残基 B 的链延长。最终 Pd/C 介导的脱保护确保 O-乙酰基稳定性。所有目标分子都代表了福氏链球菌 6 的 O 抗原的一部分,这是一种流行的血清型。非 O-乙酰化寡糖也是大肠杆菌 O147 O-抗原的片段。噻吩基 2-脱氧-2-三氯乙酰胺-D-吡喃半乳糖苷前体优选用于涉及残基 B 的链延长。最终